Evaluation of benign vs malignant hepatic lesions with positron emission tomography

Archives of Surgery

Volumn 133, Issue 5, 1998, Pages 510-516

  Delbeke, Dominique ^a   Martin, William H ^a   Sandler, Martin P ^a   Chapman, William C ^a   Wright Jr , J Kelly ^a   Pinson, C Wright ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; HUMAN; IMAGE QUALITY; LIVER ABSCESS; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031955474     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.133.5.510     Document Type: Article

References (35)

1. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495.
2. Monakhov NK, Neistadt EI, Shavlovskii MM, Shvartsman AL, Neifakh SA. Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst. 1978;61:27-34.
3. Knox WE, Jamdar SC, Davis PA. Hexokinase, differentiation, and growth rates of transplanted tumors. Cancer Res. 1970;30:2240-2244.
4. 18F]fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
5. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intra-arterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. 1988;150:189-197.
6. Wahl RL. Positron emission tomography: applications in oncology. In: Murray IPC, EII PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Scotland: Churchill Livingstone Inc: 1994:801-820.
7. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 1994;191:371-377.
8. Vitola JV, Delbeke D, Sandler MPS, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996; 171:21-26.
9. 18F]fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer. 1996;78:2216-2222.
10. Delbeke D, Vitola JV, Sandler MPS, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196-1201.
11. 18F]2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978;19:1154-1161.
12. Weber G, Cantero A. Glucose-6-phosphatase activity in normal, precancerous, and neoplastic tissues. Cancer Res. 1955;15:105-108.
13. Weber G, Morris HP. Comparative biochemistry of hepatomas, III: carbohydrate enzymes in liver tumors of different growth rates. Cancer Res. 1963;23: 987-994.
14. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992;33:333-339.
15. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET. J Nucl Med. 1995;36: 1811-1817.
16. Messa C, Choi Y, Hoh CK, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr. 1992;16:684-689.
17. Front D, Royal HD, Israel O, Parker JA, Kolodny GM. Scintigraphy of hepatic hemangiomas: the value of Tc 99m-labeled red blood cells: concise communication. J Nucl Med. 1981;22:684-687.
18. Welch TJ, Sheedy PF II, Johnson CM, et al. Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy. Radiology. 1985;156:593-595.
19. Lisbona R, Mishkin S, Derbekyan V, Novales-Diaz JA, Roy A, Sanders L. Role of scintigraphy in focally abnormal sonograms of fatty livers. J Nucl Med. 1988; 29:1050-1056.
20. Berkerman C, Hoffer PB, Bitran JD. The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med. 1985;15:72-103.
21. Abdel-Dayem H, Larson SM, Macapinlac H, Scott A. Thallium-201 chloride: a tumour imaging agent. In: Murray IPC, EII PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Scotland: Churchill Livingstone Inc; 1994: 727-735.
22. Lomas F, Dibos PE, Wagner HN. Increased specificity of liver scanning with the use of gallium-67 citrate. N Engl J Med. 1972;286:1323-1329.
23. Britton KE, Granowska M. The diagnostic role of radiolabeled antibodies. In: Murray IPC, EII PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Scotland: Churchill Livingstone Inc; 1994:779-780.
24. Markowitz A, Saleemi K, Freeman LM. Role of In 111-labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma. Clin Nucl Med. 1993;18:685-700.
25. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Nontumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
26. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 1994;81:1666-1670.
27. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 1995;21:517-522.
28. 18]fluorodeoxyglucose in identifying operable colorectal cancer. Arch Surg. 1996;131703-707.
29. Scott AM, Akhurst T, Berlangieri SU, et al. Comparison of F-18 fluorodeoxyglucose (FDG) with positron emission tomography in the detection of recurrent colorectal carcinoma. J Nucl Med. 1996;37:132P. Abstract 519.
30. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. The role of FDG-PET in advanced primary and recurrent colorectal cancer. J Nucl Med. 1996;37:132P. Abstract 517.
31. Valk PE, Abella-Columna E, Tesar RD, Pounds TR, Haseman MK, Myers RW. Diagnostic accuracy and cost-effectiveness of whole-body PET-FDG imaging in recurrent colorectal cancer. J Nucl Med. 1996;37:132P. Abstract 518.
32. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: effect of object size. J Comput Assist Tomogr. 1979;3: 299-308.
33. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG PET in the staging and management of non-small cell lung carcinoma. J Nucl Med. 1996;37:1428-1436.
34. Valk PE, Abella-Columna E, Tesar RD, Pounds TR, Haseman MK, Myers RW. Cost-effectiveness of FDG PET imaging in preoperative staging of recurrent colorectal carcinoma. J Nucl Med. 1997;38:90P. Abstract 334.
35. Gambhir SS, Valk P, Shepherd J, Hoh C, Allen M, Phelps ME. Cost effective analysis modeling of the role of FDG PET in the management of patients with recurrent colorectal cancer. J Nucl Med. 1997;38:90P. Abstract 335.